Treatment of wAMD patients with VEGF inhibitors: Insights from the routine clinical practice in Germany – the PONS Study

Hansjürgen Agostini, S. Mueller, C. Ehlken, U. Bauer-Steinhusen, Z. Hasanbasic & T. Wilke
Background: In Germany neovascular AMD is the leading cause for severe visual impairment. In 2/3 of patients visual acuity can be maintained by intravitreal injection of VEGF inhibitors. Based on clinical studies at least 7–8 injections are required in the first year. The PONS study is evaluating[for full text, please go to the a.m. URL]